Biotechnology, pharmaceutical and medtech companies contributed about 30 percent From deal volume to overall merger and acquisition (M&A) activity in 2025.
The reason for this increase is the increasing cases of obesity and diabetes. 2025 World Obesity Atlas The total number of adults with obesity is projected to increase from 524 million to 1.13 billion between 2010 and 2030, an increase of approximately 115 percent.
With this, companies are working towards strengthening their metabolism pipelines, from improving drug delivery to extending the commercial life of their products or treatments. This also means a huge opportunity for smaller biotech firms that are proposing new solutions or clinical-stage candidates.
GLP-1 craze
In the years following the pandemic, GLP-1 drugs rise to prominenceSpecifically Novo Nordisk’s Ozempic® and Vegovy®. Addiction cases and Counterfeit goods were also reported Medications assisted in weight loss and glycemic control.
to illustrate, Spending on anti-obesity drugs (AOM) was worth approximately US$3 billion in 2020. This figure was projected to exceed US$30 billion by 2024, and is already much higher today.
IQVIA insights show the global AOM market is on track to experience compound annual growth rates 13 to 15 percent Driven by wider reach and innovative formulations, leading to 2034.
Eli Lilly’s tirazeptide is expected to be the best-selling drug globally in 2026, with revenues estimated at US$45 billion.
analysts estimate The obesity treatment market could exceed US$100 billion annually by 2030, underscoring the immense potential and urgency for key players to secure their position in the landscape.
Some have recently expanded their predictions to more specific quantities, such as TD Cowen, who now has a 2030 sales forecast Of 139 billion US dollars. Roots Analysis is projecting sales of US$180 billion by 2035 UBS Investment Bank expects 2029 GLP-1 sales will reach US$126 billion.
Investors should note that buyers are increasingly looking for assets that either shorten development timelines or provide significant differentiation. This emphasis is influencing which small biotech companies are gaining attention in the market.
M&A activity as a measure
Pharmaceutical and biotechnology companies have seen an increase in M&A activity as companies race to tackle serious health challenges and work on their treatment pipelines.
Mergers, Acquisitions and Alliances Institute notes The first quarter of 2024 is particularly busyWith deals aimed at strengthening the therapeutic portfolio and capturing growth in fast-moving markets.
Leading the deal for 2024 was the deal between Novo Holdings and Catalent, valued at US$16.5 billion. This was followed by a US$4.3 billion deal between Cyma Bay and Gilead Sciences (NASDAQ: GILD), followed by Roquette’s acquisition of Pharma Solutions for US$2.85 billion.
Prior to these, Roche Holding (OTCQX:RHHBY,SWX:ROG) acquired Carmot Therapeutics in 2023, while pharmaceutical giant Pfizer (NYSE:PFE) stepped up its investment in metabolism programs after some setbacks with its oral GLP-1 initiative.
Role of drug-delivery platforms
How a drug enters the human body is becoming as important as what the drug is made of. At the time of writing most approved GLP‑1 still require injections, and this can be a real barrier to long-term adherence and everyday use.
Oral alternatives are the obvious prize, as tablets are easier for patients to take and could open up much larger markets. But converting injectable peptides into reliable oral drugs is difficult, because consistent absorption and predictable blood levels remain scientifically challenging.
This is why many companies are betting on delivery technology rather than new molecules. An improved delivery method can make an existing drug more convenient, safer, or more tolerable, and such differentiation helps extend the commercial life of a product and potentially eliminate side effects.
When delivery platforms show human data shows they work, they suddenly become potential targets for partnerships or acquisitions. This is because they provide a faster, lower-risk path to meaningful market profits.
Lexaria Bioscience Responds with DehydraTech Platform
Lexaria Bioscience (NASDAQ:LESX), a US$22.37 million company, is developing technologies aimed at solving critical challenges in the global pharmaceutical industry.
Its DehydraTech platform, which has been in Advanced Research and Development Starting in 2015, the focus initially focused on studies assessing Pharmacokinetics. The first studies specifically looked at how efficiently its formulations could improve the speed and extent of drug delivery into the bloodstream and, in some cases, the brain after oral administration.
The company has since been evaluating DehydraTech in several therapeutic areas, most recently focusing on applying the platform to GLP-1 drugs. at least 65 patents have also been granted, while others are pending applications for diabetes, hypertension-related conditions, epilepsy, antiviral drugs, central nervous system conditions, phosphodiesterase type 5 inhibitors and others.
According to Lexaria Bioscience, DehydraTech is Only technology publicly disclosed For the ability to reduce side effects in all 3 of the top GLP-1 drugs sold in the world today: semaglutide, tirazepate, and liraglutide.
For example, common concerns with GLP-1 intake are side effects of nausea, vomiting, or diarrhea.
At the start of its 2024 trials, Lexaria shared that DehydraTech-processed Ribelsus® capsules “demonstrated better tolerance in delivering the GLP-1 drug semaglutide compared to commercially available drugs.
Raibelsus® was also developed by Novo Nordisk, primarily as an oral version of semaglutide. The drug utilizes absorption-enhancing technology to enable oral delivery of a peptide that would otherwise require injection.
dehydratech experience
Lexaria explains that oral GLP-1 medications often provide similar results to injectable GLP-1 medications.
Company cites study Funded by Novo Nordisk (NYSE:NVO): “For example, in a 2021 study, patients who took weekly semaglutide injections lost an average of 15 percent of their body weight, compared to a 2023 study of oral semaglutide, which resulted in patients losing about 15 percent of their body weight.”
Nevertheless, most patients using GLP-1 drugs have reported gastrointestinal side effects, regardless of the method of administration. in a different 2021 study Seventy-four percent of patients with injections of semaglutide, funded by Novo Nordisk, experienced these effects. A 2023 study on oral semaglutide indicated that 80 percent of patients reported side effects.
How does DehydraTech make the experience manageable? Lexaria said it is “focused on the goals of improving patient experiences through the preferred oral delivery method while preserving the efficacy of the underlying drug.”
developing dehydratech
Following a renewed focus on GLP-1, Lexaria is further developing DehydraTech with a new human clinical study to be announced in April 2026.
This time, the study will focus on the evaluation of two oral Dehydratec-formulations against the commercially available Vegovy tablets.
The inaugural study will test both tablet and capsule versions with SNAC (salcaprosate sodium) for five weeks, allowing researchers to track the drug’s behavior as levels reach a steady state. This means that the formulation will be stressed enough to see if it can provide consistent absorption and improved tolerability over time.
“If successful, the results of the study will be added to an already impressive data set, with the aim of generating interest from pharmaceutical partners interested in entering into commercial relationships incorporating Lexaria’s proprietary DehydraTech technology.” the company wrote.
value of evidence
Large pharmaceutical companies, probably most large companies in general, will not risk investing money in assets that have not demonstrated proof of concept. Particularly for biotech or pharmaceutical companies, human studies are important to eliminate risks not only from a developmental or financial perspective, but also in terms of medical and corporate integrity.
Early-stage technologies with strong clinical data, such as DehydraTech, are likely to attract significant interest given the presence of evidence. With metabolic health rapidly becoming a high-growth market, companies with unique, valuable offerings have become the smart and safe choice.
Strategic buyers are also considering this platform technologies which can be applied to multiple indications, enabling rapid data re-use and accelerating clinical success.
Investor Takeaway
The simple logic in health care investing is that products backed by solid human data are far more reliable. Companies that demonstrate safety and effectiveness in people, not just in theory, command more confidence from investors.
Without that verification, the risk is fatal. This makes faith come alive.
Additionally, platforms that can make existing drugs easier to take or more tolerable in the long run become competition in acquisition negotiations.
For small biotechs, this is where the opportunity lies. If a technology shows clear results in people, it becomes far more attractive as a partner or buyout candidate. Lexaria’s recent GLP‑1 study with its DehydraTech platform is a good example, as it highlights how clinical milestones can turn a delivery concept into a strategic asset.
Human validation and patient experience remain important, and this is where the sector is likely to see the next wave of partnerships or acquisitions.
This INNspired article is sponsored by Lexaria Bioscience (NASDAQ:LEXX). it inninspired The article provides information that was sourced and approved by the Investing News Network (INN) Lexaria Bioscience To help investors learn more about the company. Lexaria Bioscience Is a customer of INN. To create and update the INN, one has to pay the company’s campaign fee. inninspired Article.
it inninspired The article was written in accordance with INN editorial standards to educate investors.
INN does not provide investment advice and the information in this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any profiled company.
The information contained herein is for information purposes only and should not be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all publicly available information related to the Company. Before taking any investment decision, it is recommended to consult readers directly Lexaria Bioscience And seek advice from a qualified investment advisor.
